Soria

Researchers are evaluating the safety and effectiveness of subcutaneous immunotherapy in patients aged 12 to 65 who have rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma, and who are sensitive to cupressaceae and grass pollen. This phase 3, multicenter, randomized, double-blinded, placebo-controlled trial aims to better understand treatment options for allergy symptoms related to these pollens. Participants will be randomly assigned to one of three groups two groups receiving different doses of a purified and polymerized allergen extract from grasses and cupressaceae mixed with aluminum hydroxide, and one placebo group receiving a similar solution without active ingredients. The treatment will be given by subcutaneous injections and will last for 18 months. The study will monitor symptoms and medication use during the specific pollen seasons for cupressaceae January to March and grasses May to June. Throughout the trial, participants will record their symptoms and medication intake using an electronic diary via a smartphone. Researchers will assess combined symptom and medication scores as the primary outcome, along with various secondary measures such as symptom-free days, medication-free days, asthma and rhinitis symptom scores, quality of life, immunological parameters, and safety. The total participation time for each subject is 18 months, during which their health and response to treatment will be closely monitored.

This research aims to evaluate the effects of melatonin supplementation combined with a physical training program on women over 60 years old who have previously had breast cancer. Breast cancer remains a leading cancer in women, and treatments often cause muscle loss, fatigue, reduced physical function, and lower quality of life. Melatonin, a hormone with multiple protective roles including anti-cancer actions, is being studied here for its potential to improve these complications when taken alongside exercise. Participants are randomly assigned to one of two groups one receives 6 mg of melatonin daily two capsules at bedtime for 10 weeks, and the other receives a matching placebo. Both groups follow a physical activity program adapted to their age and abilities. The study is double-blind, meaning neither participants nor researchers know who receives melatonin or placebo during the trial period. During the study, researchers will assess muscle damage markers, hormone levels, antioxidants, proteins related to exercise effects, physical performance tests, body measurements, and quality of life using questionnaires. These measurements are taken at the start and after 10 weeks of supplementation. The study monitors overall health, physical function, and wellbeing to understand melatonins impact in this population, with participation lasting about 10 weeks.